In a phase II study, cabozantinib, targeting VEGFR, MET, and RET, was shown to have an ORR of 28%, a median PFS of 5.5 months, and a median OS of 9.9 months in 26 RET fusion-positive NSCLC patients [20]. The gene discussed is MET; the disease is non-small cell lung carcinoma.